CP测试
Search documents
盛合晶微(A22113):盛合晶微(X25194):国内先进封测领军者三大业务协同发力
Guotou Securities· 2026-03-17 13:20
Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company, Shenghe Jingwei, has rapidly grown to become a leading player in advanced packaging and testing in China, with a revenue CAGR of 58.7% from 2022 to 2025, increasing from 1.633 billion to 6.521 billion yuan [17] - The company has successfully turned around its profitability, with net profit rising from -329 million yuan to 923 million yuan during the same period [17] - Shenghe Jingwei's business model focuses on three main areas: mid-stage silicon wafer processing, wafer-level packaging, and chiplet integration packaging, which are all strategically aligned to capture market opportunities [12][15] Summary by Sections 1. Company Overview - Shenghe Jingwei was established in 2014 as a joint venture and has evolved into a leading advanced packaging enterprise, with significant partnerships with top global chip design and manufacturing companies [12] - The company has achieved the largest 12-inch Bumping capacity and revenue in mainland China, positioning itself as a key player in the semiconductor industry [12] 2. Mid-Stage Silicon Wafer Processing - The company leads the domestic market with a 25% market share in 12-inch Bumping capacity, with revenues growing from 618 million yuan in 2022 to 1.446 billion yuan in 2024, reflecting a CAGR of 53% [33][46] - The independent CP testing segment has also shown strong growth, with a revenue of 309 million yuan in 2024, ranking second in the domestic market [15] 3. Wafer-Level Packaging - The company has achieved a 31% market share in 12-inch WLCSP, with revenues increasing from 442 million yuan in 2022 to 849 million yuan in 2024, a CAGR of 38.6% [4][15] - The company is also advancing in FOWLP technology, which is currently in small-scale trial production [4] 4. Chiplet Integration Packaging - Shenghe Jingwei holds an 85% market share in the domestic 2.5D integration segment, with projected revenues of 1.96 billion yuan in 2024 [5][15] - The company is actively developing 3DIC and 3D Package technologies, with plans for mass production in the coming years [5][15] 5. Financial Performance - The company's revenue structure has shifted significantly, with chiplet integration becoming the largest revenue source, accounting for 56% of total revenue in the first half of 2025 [19] - Gross margin improved from 7.32% in 2022 to 31.79% in 2025H1, driven by the higher contribution from chiplet integration [20] 6. Shareholding Structure - The company operates without a controlling shareholder, with significant employee ownership at 4.53%, indicating strong alignment between management and shareholder interests [22][25] 7. Expansion Plans - Shenghe Jingwei plans to invest 11.4 billion yuan to expand its 2.5D and 3DIC capacities, aiming to capture the growing demand in the chiplet integration market [31][34]
IC测试产业国产化空间广阔
Guolian Securities· 2025-05-18 16:05
Investment Rating - Investment recommendation: Outperform the market (maintained) [6] Core Insights - The IC testing industry has significant potential for domestic growth, with the independent third-party testing model gaining traction as semiconductor processes advance and reliability requirements increase [7][9] - The market size for IC testing in mainland China is estimated to be approximately 38.3 billion RMB in 2023, with a year-on-year growth of 6% [8][22] - Taiwan's IC testing output is projected to reach approximately 200.2 billion NTD in 2024, reflecting a year-on-year growth of 5.04% [21] Summary by Sections 1. IC Testing Industry Domestic Growth Potential - IC testing is a critical segment of the semiconductor supply chain, encompassing CP testing for processed wafers and FT testing for packaged chips [7][13] - The independent third-party testing model is emerging as a response to increasing demands for chip performance verification [7][13] 2. Investment Recommendations - Focus on the domestic IC testing industry chain, with particular attention to companies like Changdian Technology and Tongfu Microelectronics, as high-end testing and reliability testing are expected to see increased demand [31][32] - The computing power industry is also highlighted, with recommendations to monitor companies like Tongfu Microelectronics and Yake Technology due to the growth in AI applications [33] - The recovery of consumer electronics and the launch of AI terminal products suggest a positive outlook for companies like Luxshare Precision [34]
伟测科技(688372):景气复苏带动稼动率回暖,持续加码高端产能建设
Shenwan Hongyuan Securities· 2025-04-29 05:47
Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Insights - The company reported a revenue of 1.077 billion yuan for 2024, representing a year-over-year increase of 46.21%. The net profit attributable to shareholders was 128 million yuan, up 8.67% year-over-year [4]. - In Q1 2025, the company achieved a revenue of 285 million yuan, marking a 55.39% year-over-year growth, and a net profit of 26 million yuan, indicating a turnaround from losses [4]. - The company is increasing its investment in high-end production capacity and has completed significant capital expenditures, totaling 1.483 billion yuan in 2024, to enhance its competitive position in the market [6]. Financial Data and Profit Forecast - The company’s total revenue is projected to grow from 1.401 billion yuan in 2025 to 2.306 billion yuan by 2027, with year-over-year growth rates of 30.1%, 29.1%, and 27.6% respectively [5]. - The net profit attributable to shareholders is expected to rise from 187 million yuan in 2025 to 386 million yuan in 2027, with corresponding year-over-year growth rates of 46.0%, 43.0%, and 44.1% [5]. - The earnings per share are forecasted to increase from 1.64 yuan in 2025 to 3.39 yuan in 2027 [5]. Revenue and Profitability Analysis - The company’s revenue from CP testing reached 615 million yuan in 2024, a 38.91% increase year-over-year, while FT testing revenue was 367 million yuan, up 50.07% year-over-year [6]. - The gross margin for CP testing was 42.45%, and for FT testing, it was 29.16%, with slight decreases compared to the previous year [6]. - The company’s R&D investment increased by 37.16% year-over-year to 142 million yuan, reflecting a commitment to innovation and development [6].